Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05036226 · ClinicalTrials.gov registry record · Phase 1
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
A Phase 1 study of Solid Tumor, Adult and Prostate Cancer Recurrent, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT05036226 is a Phase 1 study of Solid Tumor, Adult and Prostate Cancer Recurrent that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 76 participants, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05036226, a Phase 1 study of Solid Tumor, Adult and Prostate Cancer Recurrent, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinavir and are given orally.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Hydroxychloroquine, Metformin, Sirolimus
- COMBINATION_PRODUCT Hydroxychloroquine, Metformin, Sirolimus, Dasatanib
- COMBINATION_PRODUCT Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
- COMBINATION_PRODUCT Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2027-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05036226
The ClinicalTrials.gov registry entry for NCT05036226 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (60% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 4 interventions - of which Hydroxychloroquine, Metformin, Sirolimus is the first listed.
NCT05036226 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT05036226 about?
NCT05036226 is a clinical study titled "COAST Therapy in Advanced Solid Tumors and Prostate Cancer". The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinavir and are given orally.
What is the current status of trial NCT05036226?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2022-03-03. Estimated completion is 2027-05-21.
What conditions does trial NCT05036226 study?
This clinical trial studies the following conditions: Solid Tumor, Adult, Prostate Cancer Recurrent.
What interventions are being tested in trial NCT05036226?
The interventions under investigation include: Hydroxychloroquine, Metformin, Sirolimus (COMBINATION_PRODUCT), Hydroxychloroquine, Metformin, Sirolimus, Dasatanib (COMBINATION_PRODUCT), Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir (COMBINATION_PRODUCT), Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05036226?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05036226 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.